Is Tirzepatide Like Mounjaro, or Are They Actually the Same Thing?

You searched for tirzepatide and landed here, here is what happened

Picture the scene: you read a clinical article, a news piece, or a conversation with your GP where someone mentioned tirzepatide. Then you searched online and found Mounjaro everywhere instead. It can feel as though the two things are related but somehow different, a branded version versus a generic, perhaps, or a diabetes drug versus a weight-loss one.

None of that is quite right. Tirzepatide is simply the international non-proprietary name (INN) for the molecule. Mounjaro is what Eli Lilly calls it on the box. In the same way that ibuprofen and Nurofen describe the same compound, tirzepatide and Mounjaro are identical. A prescription for tirzepatide dispensed by a UK pharmacy will be filled with Mounjaro, because that is the only licensed tirzepatide product available here.

The confusion is understandable. In the United States the same molecule is sold under a second brand name, Zepbound, specifically for weight management. That product does not exist in the UK, Mounjaro carries both the weight-loss and type 2 diabetes licence here. So if you have seen Zepbound mentioned and wondered whether it is different again, the answer is: same molecule, different geography, different box.

For a fuller picture of tirzepatide's properties and what the clinical evidence shows, the tirzepatide overview on this site goes into considerably more depth.

What tirzepatide actually does inside the body, and why the dual-agonist detail matters

Most weight-loss medicines in this class target one receptor: the GLP-1 receptor, which plays a role in appetite signalling and blood-sugar regulation. Tirzepatide targets two. It activates both the GLP-1 receptor and the GIP receptor, a second gut-hormone pathway that appears to amplify the appetite-reducing effect and may influence how the body handles fat storage.

That dual action is pharmacologically novel, no other weight-management medicine licensed in the UK works this way. It is the mechanism behind the trial results that drew widespread attention: in SURMOUNT-1, a 72-week study published in the New England Journal of Medicine, participants on the 15 mg dose achieved an average body-weight reduction of around 20 to 21 percent. Those numbers surprised even researchers who were familiar with the GLP-1-only trials that preceded them.

One misconception worth setting down gently: some people assume the starting dose is the one doing the therapeutic work, and feel frustrated when early results are modest. The 2.5 mg first pen exists to let your digestive system adjust gradually, the goal at that stage is tolerability, not weight loss. The prescriber then steps the dose upward over several months, guided by how each level is tolerated. That titration schedule is set out in the patient information leaflet and reviewed at each stage by your prescribing team.

The NHS tirzepatide information page covers how the medicine works and its common side effects in plain language, and is worth bookmarking if you are early in your research.

Who the licence covers and what eligibility actually looks like in practice

In the UK, Mounjaro (tirzepatide) holds two licences: one for weight management and one for type 2 diabetes. For weight management, the licence applies to adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as high blood pressure, high cholesterol, obstructive sleep apnoea, prediabetes, or cardiovascular disease. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance.

NICE's recommendation (TA1026, published December 2024) sets stricter criteria for NHS prescribing: a BMI of 35 or above plus at least one qualifying comorbidity, accessed through a specialist service. Private access through a regulated pharmacy uses the licensed eligibility criteria, which are somewhat broader, but a prescriber still assesses the full clinical picture. A BMI figure alone does not determine the outcome, medical history, current medicines, and other factors all form part of the review.

If you are curious about how the NHS rollout is structured and whether you might qualify, the Mounjaro information page covers both NHS and private routes in detail. For a direct side-by-side read on the tirzepatide and Mounjaro relationship specifically, this page addresses that exact question.

It is also worth knowing that treatment is available as a private prescription through a GPhC-registered online pharmacy without joining an NHS waiting list, subject to a clinician confirming your suitability. If you want context on what private treatment typically costs, the Mounjaro pricing page gives an honest account of the UK market.

What to expect if you go ahead, the medicine, the pen, and what comes next

Mounjaro is supplied as a pre-filled KwikPen. Each pen contains four weekly doses, administered as a once-weekly subcutaneous injection into the abdomen, thigh, or upper arm. The injection sites are rotated each week. The pen is kept in the fridge (between 2 and 8 degrees) until use; for precise storage and travel guidance, the patient information leaflet is the definitive reference, not third-party summaries.

Side effects are predominantly gastrointestinal, particularly in the early weeks and after each dose step: nausea, loose stools, constipation, and indigestion are the most commonly reported. They are usually mild, tend to ease as the body adjusts, and are one of the main reasons the dose escalation is gradual. If symptoms are severe or persistent, contacting your prescribing team rather than waiting for the next scheduled check is the sensible approach.

For a more detailed account of what the experience of taking Mounjaro feels like week to week, this page on the day-to-day reality is a useful read. Those interested in one specific aspect of the clinical evidence (specifically what the trials show about lean muscle during treatment) can find a careful look at that on the tirzepatide and lean mass page.

If you are ready to find out whether tirzepatide suits your situation, a consultation with our prescribing team is the natural next step. Check your eligibility, the consultation is free, reviewed the same day by a GPhC-registered prescriber, and carries no obligation.